×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: Epanova | heart | drug | triglycerides | AstraZeneca

FDA OKs New Pill to Lower Triglycerides

Tuesday, 06 May 2014 12:14 PM


AstraZeneca Plc has won U.S. approval for Epanova, a new pill for heart disease.
The new pill is designed for treating people with very high levels of fatty triglycerides in their blood and was originally developed by Omthera Pharmaceuticals, which AstraZeneca acquired last year.
Epanova is an ultra-pure mixture of the free fatty acid forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), derived from fish oil.
The new drug will compete with other fish oil-based medicines such as GlaxoSmithKline Plc's Lovaza, which now faces cut-price generic competition, and Amarin Corp Plc's Vascepa.
AstraZeneca also hopes to develop a fixed-dose combination of its cholesterol-lowering drug Crestor and Epanova. The new combination, if successful, would help extend the Crestor franchise beyond 2016, when the drug's U.S. patent ends.
 

© 2021 Thomson/Reuters. All rights reserved.


Health-News
AstraZeneca Plc has won U.S. approval for Epanova, a new pill for heart disease. The new pill is designed for treating people with very high levels of fatty triglycerides in their blood and was originally developed by Omthera Pharmaceuticals, which AstraZeneca acquired last...
Epanova, heart, drug, triglycerides, AstraZeneca
127
2014-14-06
Tuesday, 06 May 2014 12:14 PM
Newsmax Media, Inc.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved